Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF) said the results from the initial stage of its phase II SCOPE trial in advanced melanoma surpassed expectations..
Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF) chief executive Professor Lindy Durrant speaks to Thomas Warner from Proactive to provide an update on the.
Scancell Holdings PLC shares surged on Tuesday after the company announced positive results from the phase 2 clinical trial of its SCIB1 treatment for advanced melanoma.
Shares in Scancell were up.
Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF), which is developing immunotherapies for cancer and infectious diseases, has announced the immediate appointment.